DrugPatentWatch Database Preview

Daiichi Sankyo Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?

DAIICHI SANKYO INC has four approved drugs.

There are three US patents protecting DAIICHI SANKYO INC drugs.

There are one hundred and six patent family members on DAIICHI SANKYO INC drugs in thirty-one countries and nine supplementary protection certificates in seven countries.

Summary for Daiichi Sankyo Inc

International Patents:	106
US Patents:	3
Tradenames:	4
Ingredients:	4
NDAs:	4

Drugs and US Patents for Daiichi Sankyo Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-001	Jan 8, 2015		RX	Yes	No
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No	7,365,205			Y
Daiichi Sankyo Inc	ROXYBOND	oxycodone hydrochloride	TABLET;ORAL	209777-002	Apr 20, 2017		RX	No	No	7,955,619		Y
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-003	Jan 8, 2015		RX	Yes	Yes	7,365,205			Y

Expired US Patents for Daiichi Sankyo Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,580,880
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	4,855,290
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,340,821

Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	30 mg		2009-02-27

Non-Orange Book US Patents for Daiichi Sankyo Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,342,014	Diamine derivatives
9,707,296	Pharmaceutical composition

International Patents for Daiichi Sankyo Inc Drugs

Country	Document Number	Estimated Expiration
Canada	2696341
South Korea	101424843
Mexico	2009010474
Taiwan	I298066

Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015 00052	Denmark		PRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
C0068	France		PRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619
0760	Netherlands		PRODUCT NAME: EDOXABAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOXABAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993 20150619
15/045	Ireland		PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Daiichi
• Daiichi Sankyo
• Daiichi Sankyo Inc